Legend Biotech Jumps 42% On New Data -- Here's What Comes Next
Legend Biotech's stock surged by 42% following promising new data regarding its Carvykti treatment. The latest CARTITUDE-4 trial results indicate improved survival rates and reduced side effects, particularly Parkinsonism. Analysts suggest that this development could signify a significant shift in the treatment landscape for multiple myeloma.
- ▪Legend Biotech's stock jumped 42% after new data was released.
- ▪The CARTITUDE-4 trial showed that earlier use of Carvykti improves survival rates.
- ▪Parkinsonism rates associated with the treatment are now reported to be below 1%.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4911368-legend-biotech-jumps-42-percent-on-new-data-heres-what-comes-next"},"author":{"@type":"Person","name":"Petri Dish…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
